| Title： | Chinese Expert Consensus on Comprehensive Lipid Management in HIV/AIDS Patients |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Clinicians in Infectious Diseases and Cardiovascular Diseases |
| Evidence classification method： | GRADE |
| Development unit： | Chinese Expert Consensus Panel on Comprehensive Lipid Management in HIV/AIDS Patients |
| Registration time: | 2023-03-15 |
| Registration number： | PREPARE-2023CN163 |
| Purpose of the guideline: | In recent years, the number of newly identified HIV/AIDS patients in China has been increasing, and the risk of HIV infection in major populations continues to rise. ASCVD（arteriosclerotic cardiovascular disease） is the most common form of NAD（non-AIDS-defining disease） in HIV/AIDS patients and the leading cause of non-AIDS related death, which greatly increases the burden of AIDS disease and seriously affects the life expectancy and long-term prognosis of HIV/AIDS patients. ASCVD is the most common combination of NAD in HIV/AIDS patients and the leading cause of non-AIDS related deaths. Currently, there is no AIDS-specific expert consensus guiding the lipid management of HIV/AIDS patients receiving long-term ART in China. Based on this situation, we invited experts in the field of infectious diseases and cardiovascular disease in China to compile a Chinese expert consensus on comprehensive lipid management for patients with HIV/AIDS, taking into account the actual antiviral treatment and cutting-edge basic/clinical research results in China. |
Latest registration
